119 191Os - revival of an out-of-favor radionuclide?  by Köster, U. & Lee, B.
S58  ICTR-PHE 2016 
 
 
Keywords: proton radiotherapy, spot asymmetry, Monte Carlo 
 
References: 
[1] V. Bohlen, et al., Nuclear Data Sheets 120, 211-214 (2014) 
[2] A. Ferrari, et al., CERN-2005-10, INFN/TC_05/11, SLAC-R-
773 (2005) 
[3] K. Parodi, et al., Phys. Med. Biol. 55 (2010) 5169–5187 
 
119 
191Os – revival of an out-of-favor radionuclide? 
U. Köster1, B. Lee2,  
1 Institut Laue-Langevin, Grenoble, France 
2 Australian National University, Canberra, Australia 
 
Purpose: Novel osmium anticancer drugs are under evaluation 
that promise superior properties with respect to traditional 
Pt based drugs [1]. Even selective action against cancer stem 
cells has been reported [2]. Radiotracer and nuclear 
medicine techniques could help in the development and 
application of these drugs. 191Os is an osmium radioisotope 
well suited for this purpose with excellent properties for 
imaging and therapy. We discuss calculated Auger electron 
spectra, production methods and prospects of applications of 
191Os. 
Methods: 191Os (T1/2=15.4 d) decays to short-lived (T1/2=4.9 s) 
191mIr that emits 129 keV γ rays (26.5% intensity) well suited 
for SPECT imaging. In the past 191Os/191mIr generators [3] were 
used to provide 191mIr for first pass radionuclide 
angiocardiography [4] or studies of renal blood flow [5], but 
no direct use of 191Os has been reported so far. Among all 
known β-emitters with days to weeks half-life 191Os sticks up 
with the lowest β decay energy of only 38 keV on average 
(114 keV maximum), corresponding to a range of about one 
cell diameter. This β radiation is supplemented by abundant 
emission of short-range conversion and Auger electrons (< 60 
keV). Consequently 191Os has also potential as therapeutic 
isotope. The Auger electron spectrum of this decay was 
calculated using the methodology described in Ref. [6]. 
Results: The figure shows the calculated electron energy 
spectrum in the β- decay of 191Os (red, left scale) and in the 
internal transition decay of 191mIr (blue and yellow, right 
scale). 
 
 
Upon β- decay of 191Os the nuclear recoil of 191mIr is <0.4 eV, 
thus avoiding breakage of chemical bonds and uncontrolled 
translocation of 191mIr, provided the chemical valency change 
is tolerated. 
Direct production by 190Os(n,γ)191Os in a high thermal neutron 
flux of 1.5⋅1015 n.cm-2s-1 in ILL’s high flux reactor [7] reaches 
specific activities of ≈10 GBq/mg (≈2 MBq/µmol) after 5 days 
of irradiation. 
For Os drug dosages similar to cisplatin dosage this specific 
activity is by far sufficient for preclinical and clinical SPECT 
imaging. Even shorter irradiation times can be used to 
minimize co-produced activities (192Ir, etc.). 
Conclusions: Reactor-produced 191Os has great potential as 
radiotracer for in vitro studies of sub-cellular distribution of 
Os based drugs, for preclinical and clinical in vivo studies of 
pharmacokinetics of Os based drugs and eventually even for 
combined radionuclide-chemotherapy against particularly 
resistant tumors. 
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In 1999 to 2011, 249 cancer patients received 
boronophenylalanine (BPA)-mediated boron neutron capture 
therapy (BNCT) in Finland. Over one hundred of these 
patients were treated within the context of clinical trials. 
The purpose of the trials was to investigate the efficacy and 
safety of BNCT in the treatment of malignant gliomas (newly 
diagnosed or gliomas that progressed after surgery and 
radiotherapy) [1,2], and inoperable head-and-neck cancers 
that had recurred locally after external radiotherapy [3,4]. 
In BNCT, the absorbed radiation dose results from four main 
components: 1) the therapeutically desired high-LET 
